Although the aforementioned SOD1 trial did not meet clinical endpoints, a somewhat hopeful outcome was the observation that the levels of neurofilament light protein, a surrogate marker of ALS disease severity, were reduced in trial participants who were on the treatment. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.